Primary tracheal tumors are rare, constituting approximately 0.1–0.4% of malignant
diseases. Squamous cell carcinoma (SCC) and adenoid cystic carcinoma (ACC) account for …

Objectives There is a dearth of prospective evidence regarding cancer of the major salivary
glands. Outcomes and management of major salivary gland are based largely on …

Background Given the aggressive behavior of advanced salivary malignancies, the purpose
of the current study was to explore the utility of adjuvant chemoradiotherapy (CRT) in this …

Introduction Adenoid cystic carcinoma (AdCC) is a rare tumour as it accounts for about 10%
of all salivary gland neoplasms. It occurs in all age groups with a predominance of women …

Introduction: Salivary gland carcinomas (SGC) are histologically diverse cancers and next-
generation sequencing (NGS) to identify key molecular targets is an important aspect in the …

BACKGROUND: Bortezomib, an inhibitor of the 26S proteasome and NF‐κB, may have
antitumor activity in adenoid cystic carcinoma (ACC). Preclinical studies have shown …

Background: Sinonasal adenoid cystic carcinoma (SNACC) presents a challenge to
oncologists due to its complex anatomy and poor prognosis. Although radiation therapy …

Background Salivary duct carcinoma (SDC) and adenocarcinoma, not otherwise specified
(adeno‐NOS), are rare salivary gland cancers. Data on the efficacy of systemic therapy for …

Effective treatment options for advanced salivary gland tumors are lacking. To better
understand these tumors, we report their genomic landscape. We studied the molecular …

Malignant salivary gland tumors make up a small proportion of malignancies worldwide, yet
vary widely in terms of histology, patterns of spread, and recurrence. A better understanding …